Boothbay Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
Other funds holding RIGL
AC
Boothbay Fund Management's RIGL Position: Q3 2022 in Review
Boothbay Fund Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 9,688 shares — an estimated $109K sold.
Boothbay Fund Management first reported a position in RIGL in Q1 2015 and held it in 18 quarters. The position peaked at $778K in Q1 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.
- Boothbay Fund Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Boothbay Fund Management sold 9,688 Rigel Pharmaceuticals shares in Q3 2022, an estimated $109K.
- Boothbay Fund Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 18 quarters.
- Boothbay Fund Management's Rigel Pharmaceuticals position peaked at $778K in Q1 2022.
- 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.
Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.